Spire Wealth Management Has $37,000 Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Spire Wealth Management raised its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 49.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,209 shares of the company’s stock after purchasing an additional 1,400 shares during the quarter. Spire Wealth Management’s holdings in Teva Pharmaceutical Industries were worth $37,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in TEVA. Bank of New York Mellon Corp raised its stake in Teva Pharmaceutical Industries by 1.6% during the 1st quarter. Bank of New York Mellon Corp now owns 1,875,394 shares of the company’s stock valued at $17,609,000 after purchasing an additional 28,920 shares during the period. PNC Financial Services Group Inc. increased its stake in shares of Teva Pharmaceutical Industries by 12.3% in the first quarter. PNC Financial Services Group Inc. now owns 119,076 shares of the company’s stock worth $1,118,000 after acquiring an additional 13,069 shares during the last quarter. MetLife Investment Management LLC increased its stake in shares of Teva Pharmaceutical Industries by 4.7% in the first quarter. MetLife Investment Management LLC now owns 95,953 shares of the company’s stock worth $901,000 after acquiring an additional 4,300 shares during the last quarter. BlackRock Inc. increased its stake in shares of Teva Pharmaceutical Industries by 3.7% in the first quarter. BlackRock Inc. now owns 41,648,716 shares of the company’s stock worth $391,081,000 after acquiring an additional 1,494,814 shares during the last quarter. Finally, Great West Life Assurance Co. Can increased its stake in shares of Teva Pharmaceutical Industries by 4.0% in the first quarter. Great West Life Assurance Co. Can now owns 420,533 shares of the company’s stock worth $4,137,000 after acquiring an additional 16,134 shares during the last quarter. 49.69% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, CFO Eliyahu Sharon Kalif sold 35,125 shares of the firm’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $9.73, for a total value of $341,766.25. Following the sale, the chief financial officer now owns 99,162 shares of the company’s stock, valued at approximately $964,846.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CFO Eliyahu Sharon Kalif sold 35,125 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $9.73, for a total transaction of $341,766.25. Following the sale, the chief financial officer now owns 99,162 shares of the company’s stock, valued at approximately $964,846.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Eric A. Hughes sold 52,742 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $8.30, for a total value of $437,758.60. The disclosure for this sale can be found here. Insiders have sold 89,848 shares of company stock valued at $799,176 in the last 90 days. 0.62% of the stock is currently owned by insiders.

Analyst Ratings Changes

TEVA has been the topic of a number of research reports. Morgan Stanley initiated coverage on shares of Teva Pharmaceutical Industries in a research note on Thursday, May 25th. They issued an “equal weight” rating and a $10.00 price target on the stock. StockNews.com initiated coverage on shares of Teva Pharmaceutical Industries in a research note on Thursday, August 17th. They issued a “buy” rating on the stock. Evercore ISI raised shares of Teva Pharmaceutical Industries from an “in-line” rating to an “outperform” rating in a research note on Thursday, May 18th. Finally, UBS Group upgraded Teva Pharmaceutical Industries from a “sell” rating to a “neutral” rating and raised their target price for the company from $7.00 to $8.00 in a report on Thursday, July 6th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $10.14.

Teva Pharmaceutical Industries Stock Up 0.3 %

Shares of TEVA stock opened at $9.70 on Friday. The stock’s 50 day simple moving average is $8.57 and its 200 day simple moving average is $8.68. The company has a debt-to-equity ratio of 2.43, a quick ratio of 0.67 and a current ratio of 1.02. Teva Pharmaceutical Industries Limited has a twelve month low of $7.09 and a twelve month high of $11.44. The company has a market capitalization of $10.86 billion, a price-to-earnings ratio of -4.85, a PEG ratio of 1.59 and a beta of 1.20.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, August 2nd. The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.52 by $0.02. The firm had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.69 billion. Teva Pharmaceutical Industries had a positive return on equity of 27.93% and a negative net margin of 14.87%. As a group, research analysts predict that Teva Pharmaceutical Industries Limited will post 2.16 EPS for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.